CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1031-1037

  Kayal, Smita ^a   Mathur, Sandeep ^b   Karak, Asis K ^b   Kumar, Lalit ^a   Sharma, Atul ^a   Bakhshi, Sameer ^a   Raina, Vinod ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

CD68; Hodgkin lymphoma; India; Prognosis; Tumor associated macrophage

Indexed keywords

BLEOMYCIN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLASSICAL HODGKIN LYMPHOMA; CORRELATION ANALYSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; AGED; CANCER GRADING; HODGKIN DISEASE; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; REMISSION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84899734763     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.824079     Document Type: Article

References (26)

1. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004; 5: 19-26.
2. Bjö r kholm M, Axdorph U, Grimfors G, et al. Fixed versus responseadapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol 1995; 6: 895-899.
3. Smithers DW. Summary of papers delivered at the conference on staging in Hodgkin's disease (Ann Arbor). Cancer Res 1971; 31: 1869-1870.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
5. Sup SJ, Alemañy CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: An independent predictor of poor outcome. J Clin Oncol 2005; 23: 3773-3779.
6. Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007; 25: 3101-3108.
7. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I , et al. Topoisomerase II alpha expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008; 14: 1759-1766.
8. Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3-regulatory T cells to granzyme B-cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128: 958-965.
9. Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-1473.
10. Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010: 93-100.
11. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612.
12. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-Associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-2174.
13. Steidl C, Lee T, Shah SP, et al. Tumor-Associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
14. DeVita VT Jr. A breakthrough in Hodgkin's disease. Nat Rev Clin Oncol 2010; 7: 179.
15. Diehl V. Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010; 7: 301-302.
16. Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor-Associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012; 23: 736-742.
17. Benedicte D, Emmanuel B, Vincent R, et al. Macrophages and mast cells infi ltration are biomarkers of primary refractory Hodgkin's lymphoma. Blood 2010; 116(Suppl. 1): Abstract 3881.
18. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Hematol 2012; 88: 292-305.
19. Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infi ltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011; 96: 269-276.
20. Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013; 31: 256-262.
21. Diehl V, Fuchs M. E arly, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies. Ann Oncol 2007; 18(Suppl. 9): Ix71-ix79.
22. Ganesan P, Kumar L, Raina V, et al. Hodgkin's lymphoma-longterm outcome: An experience from a tertiary care cancer center in north india. Ann Hematol 2011; 90: 1153-1160.
23. De Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications-A study from the Lunenburg lymphoma biomarker consortium. J Clin Oncol 2007; 25: 805-812.
24. Pulford KA, Sipos A, Cordell JL, et al. Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol 1990; 2: 973-980.
25. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: Tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
26. Sá nchez-Aguilera A, Montalb á n C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006; 108: 662-668.